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Abstract
Objective A practical screening tool for chronic mesenteric ischemia (CMI) could facilitate early recognition and reduce
undertreatment and diagnostic delay. This study explored the ability to discriminate CMI from non-CMI patients with a mesen-
teric artery calcium score (MACS).
Methods This retrospective study included CTAs of consecutive patients with suspected CMI in a tertiary referral center between
April 2016 and October 2019. A custom-built software module, using the Agatston definition, was developed and used to
calculate the MACS for the celiac artery (CA), superior mesenteric artery (SMA), and inferior mesenteric artery. Scoring was
performed by two blinded observers. Interobserver agreement was determined using 39 CTAs scored independently by both
observers. CMI was defined as sustained symptom improvement after treatment. Non-CMI patients were patients not diagnosed
with CMI after a diagnostic workup and patients not responding to treatment.
Results The MACS was obtained in 184 patients, 49 CMI and 135 non-CMI. Interobserver agreement was excellent (intraclass
correlation coefficient 0.910). TheMACSof all mesenteric arteries was significantly higher in CMI patients than in non-CMI patients.
ROC analysis of the combined MACS of CA + SMA showed an acceptable AUC (0.767), high sensitivity (87.8%), and high NPV
(92.1%), when using a ≥ 29.7 CA + SMAMACS cutoff. Comparison of two CTAs, obtained in the same patient at different points in
time with different scan and reconstruction parameters, was performed in 29 patients and revealed significant differences in MACSs.
Conclusion MACS seems a promising screening method for CMI, but correction for scan and reconstruction parameters is warranted.
Key Points
• Amesenteric artery calcium score obtained in celiac artery and superior mesenteric artery has a high negative predictive value
for chronic mesenteric ischemia and could serve as a screening tool.
• Interobserver agreement of the mesenteric artery calcium score is excellent.
• Scan and reconstruction parameters influence the mesenteric artery calcium score and warrant the development of a method to
correct for these parameters.
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Abbreviations
AUC Area under the curve
CA Celiac artery
CACS Coronary artery calcium score
CI Confidence interval
CMI Chronic mesenteric ischemia
CT Computed tomography
CTA Computed tomography angiography
CVD Cardiovascular disease
HU Hounsfield unit
ICC Intraclass correlation coefficient
IMA Inferior mesenteric artery
IQR Interquartile range
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MACS Mesenteric artery calcium score
MALS Median arcuate ligament syndrome
NPV Negative predictive value
PPV Positive predictive value
Sd Standard deviation
SMA Superior mesenteric artery
VLS Visible light spectroscopy
Introduction
Postprandial abdominal pain and weight loss caused by fear of
eating are incapacitating complaints associated with chronic
mesenteric ischemia (CMI) [1, 2]. When left untreated, CMI
has been reported to progress to acute mesenteric ischemia in
26–67% of patients [3, 4]. A recent study reported an overall
annual CMI incidence of 9.2 per 100,000 inhabitants [5]. As
previously shown, this study also reported atherosclerotic CMI
(7.3 per 100,000) to be the greatest contributor to the overall
incidence [5–7]. The incidence of atherosclerotic CMI showed
a rising trend over the study period, suggesting that atheroscle-
rotic CMI is an upcoming health issue. European experts agree
that CMI still remains an underdiagnosed and undertreated dis-
ease, which is mainly caused by a lack of knowledge and
awareness among physicians [8]. This observation is supported
by a substantial diagnostic delay of approximately 6 months
after onset of complaints [5, 9].
An easy to use non-invasive screening tool for CMI could
facilitate early recognition and increase awareness for CMI,
reducing undertreatment, diagnostic delay, and progression to
acute mesenteric ischemia. The Agatston coronary artery cal-
cium score (CACS) has been used to assess the risk of coro-
nary artery disease and aid in clinical decision-making [10,
11]. A CACS of 0 has been shown to have a very high neg-
ative predictive value (NPV) of coronary artery disease [12].
A mesenteric artery calcium score (MACS) based on the same
principles as the CACS could serve as a potential first test to
identify patients in whom CMI is unlikely and identify pa-
tients in whom a further diagnostic workup is warranted.
This study aimed to explore the ability to discriminate CMI
patients from patients without CMI by using a MACS.
Methods
Study design
This single-center retrospective cohort study included consec-
utive patients analyzed for suspected CMI in a specialized
tertiary referral center between April 2016 and October
2019. Patients were eligible for inclusion when a computed
tomography (CT)—not older than 12 months before first
presentation—was available. Patients were excluded when
they had undergone a previous mesenteric artery revasculari-
zation, when an anatomical variation with a common origin of
the celiac artery (CA) and superior mesenteric artery (SMA)
was present, or when the duration of clinical follow-up after
mesenteric artery revascularization was less than 3 months.
The local medical research ethics committee decided that the
Medical Research Involving Human Subjects Act does not
apply to this study (MEC-2018-1414). The investigators com-
plied with the Helsinki declaration on research ethics. The
STROBE checklist for cohort studies was used to write this
manuscript [13].
Diagnostic workup of chronic mesenteric ischemia
A standardized diagnostic workup was performed in all pa-
tients and consisted of an assessment of symptoms, computed
tomography angiography (CTA), and when indicated assess-
ment of mucosal ischemia by visible light spectroscopy (VLS)
[14]. Results of the workup were discussed by an experienced
multidisciplinary expert team consisting of gastroenterolo-
gists, interventional radiologists, and vascular surgeons.
Patients were treated when a consensus diagnosis of CMI
was established, which was based on presenting symptoms,
imaging, VLS, and absence of a possible alternative diagnosis
[15]. A definitive diagnosis of CMI was established when
symptoms improved or resolved at three months after revas-
cularization, or in case of chronic non-occlusive mesenteric
ischemia during treatment with a vasodilator. Patients with a
consensus diagnosis of no CMI or those initially labeled as
CMI, but without improvement of symptoms after treatment,
were classified as non-CMI. A definitive diagnosis of CMI
was used for the primary outcome, which was to determine
the ability of the MACS to discriminate patients with a defin-
itive diagnosis of CMI from non-CMI patients.
Calcium scoring tool
The majority of the available CTs were contrast enhanced,
which is explained by the fact that a CTA is indicated in the
workup of CMI in order to assess vessel patency. When mul-
tiple series with different contrast enhancement phases were
available, the series with the lowest slice thickness, generally
the arterial contrast enhancement series, was used to calculate
the MACS. Available semi-automated calcium scoring soft-
ware can not differ calcified plaques from contrast; i.e., con-
trast is labeled as calcium, and therefore not suitable for use
within this study. A custom-built software module in
MeVisLab version 2.7.1 (MeVis Medical Solutions AG)
was developed to identify calcified lesions by assigning hand
drawn regions of interest on CTA (Fig. 1). The MACS was
calculated according to the Agatston definition, which is cal-
culated by multiplying the volume of a lesion with a density
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factor [10]. To assess the technical accuracy of the software,
the CACS of six cardiac CTs without contrast enhancement
analyzed by both Syngo.via (Siemens Healthcare) and by
MeVisLab were compared.
Mesenteric artery calcium score
The MACS was obtained for all three mesenteric arteries in-
dividually; the total MACS was the sum of the MACS of the
CA, SMA, and inferior mesenteric artery (IMA). Mesenteric
artery stenoses most frequently occur at the origin of a mes-
enteric artery and involve the aorta wall directly surrounding
the origin; distal stenoses are less common [16, 17].
Assumptions were made to standardize the areas of calcium
scoring. The estimated volume of a calcified lesion causing a
stenosis at the vessels’ origin consisted of the volume of the
lesion that was located within a circle with a radius of 1 time
the diameter of the vessels’ origin (Fig. 2). Calcium scoring
was performed from origin until bifurcation for CA, from
origin until the first large jejunal artery for SMA, and from
origin until left colic artery for IMA.
Calcium scoring was performed by two observers, an in-
terventional radiologist with 9 years of experience and a train-
ee with little experience. Both observers were blinded to pa-
tient history and clinical outcome. The first 9 CTAs served as
a training set and were reviewed by both observers; scoring
was performed based on consensus. The following 39 CTAs
were used to determine interobserver agreement and scored
independently by both observers, while remaining blinded to
each other’s results. A sample size of 13 CTAs would suffice
for assessment of the intraclass correlation coefficient (ICC),
when comparing results of two observers, while using an al-
pha of 0.05 and a beta of 0.1 [18]. However, an atherosclerotic
stenosis is observed in approximately 43–53% of patients [5,
7]. The required sample size of 13 CTAs was tripled to 39
CTAs in order to include sufficient CTAs with calcified le-
sions, since interobserver variability is expected to be greater
when scoring CTAs with calcifications. Interobserver agree-
ment was assessed directly upon completion of the 39 CTAs.
When the interobserver agreement was good (ICC 0.75 to 0.9)
or excellent (ICC ≥ 0.9), the remaining CTAs would be scored
by either one of the observers [19]. When the interobserver
agreement was poor (ICC < 0.5) or moderate (ICC 0.5 to
0.75), the remaining CTAs would be scored by both
observers.
Variability scan protocols
The vast majority of patients were referred by other hospitals
and CTA imaging had often been performed in the referring
hospital, causing a large variety in the used scan protocols. A
CTA, performed using a standardized mesenteric artery pro-
tocol, was repeated during the workup when the image quality
was deemed insufficient to reliably assess mesenteric artery
patency. When two scans of the same patient were available
calcium scoring was performed on both scans. Both scans had
to be performed within 12 months before presentation, since
clinically significant progression of atherosclerosis was ex-
pected to be unlikely within this time window. The scan
Fig. 1 Regions of interest for calculation of the mesenteric artery calcium
score on computed tomography angiography, using MeVisLab
Fig. 2 Regions included in the mesenteric artery calcium score
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performed in the tertiary referral center was included in the
analysis of the primary endpoint. A separate analysis was
performed to determine whether imaging and reconstruction
parameters influenced the MACS by comparing the MACS
and CTA characteristics—i.e., slice thickness, pixel spacing,
tube voltage, and contrast enhancement—of the two scans.
The density of contrast enhancement was calculated by the
sum of the mean and two times the standard deviation (sd)
of the Hounsfield unit (HU) value measured within the center
of the aorta at the level of the origin of the mesenteric artery.
Data collection and statistical analysis
Data regarding medical history, presenting symptoms, pres-
ence of a mesenteric artery stenosis (defined as ≥ 50% luminal
reduction), diagnosis, follow-up, CTA characteristics, density
of contrast enhancement, andMACSwere collected and pseu-
do anonymized with a unique code.
Statistical analyses were performed with R version 3.5.3 (R
Foundation for Statistical Computing) using packages pROC
and irr. Continuous variables were not equally distributed and,
therefore, shown as median and interquartile range (IQR).
Baseline characteristics of CMI and non-CMI patients were
compared using chi-square or Fisher’s exact testing for cate-
gorical variables and Wilcoxon rank testing for continuous
variables. The ICC was used to assess MACS interobserver
agreement and correlation between the CACS calculated by
Syngo.via and MeVisLab. Receiver operator characteristics
curves were computed to define MACS cutoff values to dis-
criminate CMI patients from non-CMI patients. The area un-
der the curve (AUC) was used to quantify the discriminative
ability of the MACS. An AUC of 0.5 suggests no discrimina-
tion; AUC of 0.7 to 0.8 acceptable discrimination; AUC of 0.8
to 0.9 excellent discrimination; and AUC ≥ 0.9 outstanding
discrimination [20]. The sign test was used to compare the
characteristics and MACS of two CTAs of the same patient
(obtained at two different points in time).
Results
During the study period, 203 patients were analyzed for
suspected CMI. A total of 184 patients was included in the
study. Reasons for exclusion were a previous mesenteric ar-
tery revascularization in 9 patients, a common origin of CA
and SMA in 2 patients, and a follow-up duration of < 3
months after revascularization in 8 patients. A definitive diag-
nosis of CMI was established in 49 of the included patients, of
whom 46 were diagnosed with atherosclerotic CMI, 2 with
median arcuate ligament syndrome (MALS), and 1 with
chronic non-occlusive mesenteric ischemia. The remaining
135 patients were classified as non-CMI.
Baseline and CTA characteristics
CMI patients were significantly older (CMI 70 (65–75) vs.
non-CMI 64 (56–70)) and significantly more often female
(CMI 81.6% vs. non-CMI 65.9%). Comparison of risk factors
of cardiovascular disease (CVD) showed that a history of
CVD, a history of peripheral artery disease, and smoking were
significantly more prevalent among CMI patients (Table 1).
The presenting symptoms of weight loss, postprandial abdom-
inal pain, diarrhea, and an adapted eating pattern were also
significantly more prevalent in CMI patients.
CTA revealed no mesenteric artery stenosis in 56 (30.4%)
patients, CA stenosis in 45 (24.5%) patients, SMA stenosis in
17 (9.2%) patients, IMA stenosis in 10 (5.4%) patients, CA
and SMA stenosis in 18 (9.8%) patients, CA and IMA stenosis
in 10 (5.4%) patients, SMA and IMA stenosis in 10 (5.4%)
patients, and CA, SMA, and IMA stenosis in 18 (9.8%) pa-
tients (Table 2). The nature of the stenosis was atherosclerosis
in 77.1% of patients, compression in 19.1%, iatrogenic in
2.3%, and a combination of atherosclerosis and compression
in 1.5% of patients (Table 2). Comparison of the CTA char-
acteristics of CMI and non-CMI patients did not show a sig-
nificant difference in tube voltage, slice thickness, pixel spac-
ing, or contrast density at the level of CA, SMA, or IMA.
Calcium scoring software accuracy and interobserver
agreement
The CACS on the cardiac CTs, calculated by Syngo.via and
MeVisLab, showed an excellent correlation with an ICC of
0.998 (95% confidence interval (CI) 0.991–1.000). Proving
technical accuracy after which the assessment of the MACS
was commenced. MACS of the 39 CTAs scored by both ob-
servers showed an excellent correlation as well (ICC 0.910
(95% CI 0.834–0.951)). Hence, the remaining CTAs were
scored by either one of the observers.
Mesenteric artery calcium score
The MACSs of CA, SMA, IMA, CA + SMA, and the total
MACS were all significantly higher in CMI patients than in
non-CMI patients (Table 3). The ability to discriminate CMI
patients from non-CMI patients using the MACS was
assessed by calculating the AUC. MACSs of CA + SMA
and total MACS showed the highest discriminative ability
with acceptable AUCs of 0.767 (95% CI 0.686–0.847) and
0.770 (95% CI 0.690–0.851) respectively (Table 4). The best
test characteristics for the identification of CMI patients were
found when using a MACS cutoff of ≥ 29.7 for CA + SMA:
sensitivity 87.8%, specificity 51.9%, positive predictive value
(PPV) 39.8%, and negative predictive value (NPV) 92.1%.
Seventy of the 184 (38%) patients had a MACS < 29.7 and
no definitive diagnosis of CMI.
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Influence scan protocol on calcium score
A scan performed in both the tertiary referral center and the
referring hospital was available for 29 patients. Comparison of
the CTAs showed a significant difference in the used tube
voltage and the contrast densities of the CTAs (Table 5).
The slice thickness of the tertiary referral center CTAs was
significantly thinner than the slice thickness of the CTAs of
the referring hospital (tertiary referral center 0.8 (0.8–0.9) vs.
referring hospital 3.0 (2.0–3.0)). When comparing the MACS
of both CTAs, the MACS of SMA, CA + SMA, and the total
MACS were all significantly higher when calculated on the
CTA of the referring hospital.
Discussion
This study is the first to report the use of a MACS to discrim-
inate CMI patients from non-CMI patients. A combined
MACS of CA + SMA showed most promising for this
Table 1 Baseline characteristics
Baseline characteristic All patients CMI patients Non-CMI patients p value
(N = 184) (N = 49) (N = 135)
Female gender 70.1% 81.6% 65.9% p = 0.061
Age 67 (57–73) 70 (65–75) 64 (56–70) p = 0.002
Follow-up (months) 6 (2–11) 10 (8–24) 3 (1–9) p < 0.001
Risk factors
Cardiovascular disease 44.0% 61.2% 37.8% p = 0.008
Peripheral artery disease 20.7% 42.9% 12.6% p < 0.001
Coronary artery disease 21.7% 26.5% 20.0% p = 0.455
Cerebrovascular disease 12.5% 16.3% 11.1% p = 0.488
Dyslipidemia 13.6% 16.3% 12.6% p = 0.682
Hypertension 33.2% 34.7% 32.6% p = 0.928
Diabetes 14.1% 20.4% 11.9% p = 0.217
Family history of CVD 38.9% 44.4% 36.8% p = 0.472
Smoking 66.7% 83.7% 60.3% p = 0.005
Pack years 25 (11–44) 33 (20–49) 21 (4–40) p = 0.028
Presenting symptoms
Weight loss 64.2% 93.8% 53.4% p < 0.001
Weight (kg) 64 (56–79) 61 (52–70) 66 (57–81) p = 0.147
Body mass index 23 (20–27) 21 (19–26) 23 (20–27) p = 0.114
Abdominal pain 91.3% 95.9% 89.6% p = 0.243
Duration abdominal pain (months) 10 (4–24) 5 (3–12) 12 (6–24) p = 0.047
Postprandial abdominal pain 63.5% 83.0% 55.8% p = 0.002
Exercise-induced abdominal pain 37.8% 36.4% 38.3% p = 1.000
Adapted eating pattern 55.5% 83.3% 46.4% p < 0.001
Nausea 57.3% 63.4% 54.4% p = 0.440
Diarrhea 21.2% 39.6% 14.5% p = 0.001
Numerical variables are shown as median (interquartile range); p < 0.05 is considered statistically significant
CMI, chronic mesenteric ischemia; CVD, cardiovascular disease; kg, kilogram
Table 2 Location and nature of mesenteric artery stenosis
Stenosis characteristics CMI patients Non-CMI patients
(N = 49) (N = 135)
No significant stenosis 1 (1.8%) 55 (98.2%)
CA 6 (13.3%) 39 (86.7%)
SMA 3 (17.6%) 14 (82.4%)
IMA 0 (0.0%) 10 (100.0%)
CA and SMA 13 (72.2%) 5 (27.8%)
CA and IMA 2 (20.0%) 8 (80.0%)
SMA and IMA 8 (80.0%) 2 (20.0%)
CA, SMA, and IMA 16 (88.9%) 2 (11.1%)
Nature of stenosis (N = 48) (N = 83)
Atherosclerosis 46 (45.5%) 55 (54.5%)
Compression 2 (8.0%) 23 (92.0%)
Iatrogenic 0 (0.0%) 3 (100.0%)
Atherosclerosis and compression 0 (0.0%) 2 (100.0%)
The shown data are numbers and (proportions)
CA, celiac artery; CMI, chronic mesenteric ischemia; IMA, inferior mes-
enteric artery; SMA, superior mesenteric artery
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purpose with an AUC of 0.767 and a high NPV (92.1%),
using a ≥ 29.7 cutoff for CA + SMA. Interobserver agreement
of the MACS was excellent (ICC 0.910). The used scan pro-
tocol and reconstruction parameters (slice thickness, tube volt-
age, and contrast enhancement) influenced the calculated
MACS.
Limited awareness for CMI and lack of knowledge among
physicians cause diagnostic delays. An easy to use screening
tool for CMI could shorten this diagnostic delay, but is un-
available. The CA + SMA calcium score seems able to dis-
criminate CMI patients from non-CMI patients. The discrim-
inative ability was acceptable (AUC 0.767) and the sensitivity
(87.8%) and NPV (92.1%) were high. Even though the
MACS was calculated on CTA and reconstruction parameters
varied between scans, the MACS still approximates the test
characteristics of a CACS of 0 (sensitivity 99–100%, NPV
97–100%), indicating that the CA + SMA MACS is a prom-
ising screening method [12]. A second reason to opt for use of
the CA + SMA MACS is the good recognizability of the
origin of the CA and SMA. While the identification of the
origin of the IMA can be more cumbersome, especially on
non-contrast-enhanced CT, and the addition of the IMA to
the MACS seems of limited value. Calculation of the CA +
SMAMACS on CTs of patients with weight loss or postpran-
dial abdominal pain in whom the diagnosis CMI is considered
and, in whom an alternative diagnosis is not found, is an
attractive clinical application of this score. A low calcium
score effectively rules out CMI, implying that a CTA would
not be indicated in approximately 38% of patients, which is
advantageous to patients with impaired renal function. CMI is
more probable in case of an increased CA + SMA MACS,
warranting a diagnostic workup, including a CTA with ≤ 1-
mm slice thickness to assess vessel patency [8].
The currently used software enabled calcium scoring on
contrast-enhanced CT. The interobserver agreement was ex-
cellent (ICC 0.910), even though regions of interest were
drawn by hand and were performed by an experienced
interventional radiologist and a trainee, suggesting that the
MACS on CTA does not depend on the scoring radiologist.
The 39 CTs scored by both observers included too few non-
contrast-enhanced CTs to reliably assess the effect of contrast
enhancement on the interobserver agreement of the MACS.
Observers could have falsely included contrast at the borders
of the lesion and could have missed calcifications with a low
intensity that were concealed by high intensity of contrast
enhancement, which influences reliability of the MACS. The
current necessity to draw regions of interest by hand is time
consuming, especially when the slice thickness is ≤ 1 mm.
Development of (semi-)automated calcium scoring software,
such as currently used for the CACS, should be validated for
several levels of intensity of contrast enhancement in order to
solve the limitation of contrast enhancement and make mes-
enteric artery calcium scoring fast and feasible for clinical
practice.
This retrospective study is a first attempt to identify CMI
patients using a MACS and should be considered a proof of
principle. The high NPV indicates that the MACS could po-
tentially be a much desired screening tool for CMI. However,
suggesting a suitable cutoff for clinical use is premature due to
limitations of the current study, such as the large variation in
CTA characteristics of the included scans, which influenced
the MACS when comparing two CTAs performed in one pa-
tient. The influence of tube voltage, slice thickness, and re-
construction kernel on the calcium score has already been
described in CACS literature [21–23]. The influence of tube
voltage on the CACS has recently been studied by Booij et al;
they showed that CACSs on a phantom significantly differed
when tube voltage increased [21]. Qian et al compared the
volume of coronary calcium on 0.5-mm and 3.0-mm slice
thickness reconstructions, using intravascular ultrasound with
radiofrequency backscatter-virtual histology as a reference
[22]. Reconstructions of 0.5-mm reduced the overestimation
of calcium volume as compared to conventional 3.0-mm re-
constructions and had a higher sensitivity (0.5-mm 94%, 3.0
mm-56%), but lower specificity (0.5-mm 50%, 3.0-mm 93%).
Mantini et al reported that the CACS on 0.5-mm slice thick-
ness reconstructions resulted in significant reclassification of
the cardiovascular risk when compared with standard 3.0-mm
reconstructions [23]. The use of reconstructions with a differ-
ent reconstruction kernel also resulted in significant reclassi-
fication of the cardiovascular risk, showing that variation in
the used reconstruction parameters can influence clinical de-
cision-making. The results of these studies support the ob-
served influence of scan and reconstruction parameters on
the MACS, underlining that correction factors for slice thick-
ness, tube voltage, and contrast enhancement are needed to set
a reliable MACS cutoff that is feasible for use in clinical
practice. Correction factors could be calculated by a phantom
study using different slice thicknesses, tube voltages, and in-
tensities of contrast enhancement.
Table 3 Mesenteric artery calcium scores
MACS CMI patients Non-CMI patients p value
(N = 50) (N = 134)
CA 166 (71–510) 0 (0–136) p < 0.001
SMA 463 (8–1130) 0 (0–130) p < 0.001
IMA 21 (0–66) 0 (0–19) p = 0.005
CA + SMA 832 (96–1803) 17 (0–278) p < 0.001
Total 966 (149–1701) 31 (0–351) p < 0.001
Calcium scores are shown as median (interquartile range); p < 0.05 is
considered statistically significant
CA, celiac artery; CMI, chronic mesenteric ischemia; IMA, inferior mes-
enteric artery; MACS, mesenteric artery calcium score; SMA, superior
mesenteric artery
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Other possible limitations of this study are related to the
included patient population and retrospective study design.
First, all included patients were referred because of suspected
CMI based on typical symptoms and/or mesenteric artery ste-
nosis, resulting in a population with a higher pretest probabil-
ity of CMI. However, the prevalence of CVD risk factors and
typical symptoms still differed significantly between CMI and
non-CMI patients, suggesting that the predictive value of
MACS could be improved by relating the MACS to history
and clinical symptoms. Hence, the addition of the MACS to
an existing CMI score chart could improve the accuracy of the
predicted CMI probability and possibly prevent a missed di-
agnosis of CMI in patients with a non-calcified mesenteric
artery stenosis [7]. Second, our inclusion strategy resulted in
the inclusion of two MALS patients. These patients had a
MACS of 0, since MALS is caused by CA compression and
not by atherosclerosis. MALS is typically seen in patients of
younger age, without cardiovascular risk factors [2, 24]. Non-
atherosclerotic causes of CMI, such as MALS or vasculitis,
are more probable in patients of younger age. Selection of
patients based on age, e.g., ≥ 40 years of age, could be a viable
strategy to improve the sensitivity of the MACS and avoid
false-negative tests. Third, the follow-up duration of non-
CMI patients was shorter than the follow-up duration of
CMI patients. Non-CMI patients could have been treated in
another center after their last outpatient clinic visit, although
this is unlikely, since there is only one other mesenteric ische-
mia expert center in the country. Fourth, the number of includ-
ed patients was too low to allow subgroup analysis, e.g., to
determine MACS cutoffs for each level of tube voltage.
Table 5 Comparison of CTA
characteristics and calcium scores
of CTAs of the same patient
CTA characteristics Tertiary referral center Referring hospital p value
(N = 29) (N = 29)
Tube voltage (kVp) p = 0.001
70 5 (17.2%) 1 (3.4%)
80 15 (51.7%) 4 (13.8%)
90 2 (6.9%) 1 (3.4%)
100 3 (10.3%) 11 (37.9%)
120 4 (13.8%) 12 (41.4%)
Slice thickness (mm) 0.8 (0.8–0.9) 3.0 (2.0–3.0) p < 0.001
Pixel spacing 0.7 (0.6–0.7) 0.7 (0.6–0.7) p = 0.845
Contrast density
Aorta level CA 625.1 (477.6–717.5) 213.3 (186.7–400.4) p < 0.001
Aorta level SMA 639.9 (518.5–737.5) 207.4 (180.7–402.4) p < 0.001
Aorta level IMA 637.3 (500.0–769.3) 267.2 (193.1–489.3) p < 0.001
MACS
CA 114 (0–320) 192 (0–435) p = 0.078
SMA 330 (0–577) 352 (0–945) p = 0.012
IMA 9 (0–51) 22 (0–59) p = 0.824
CA + SMA 519 (4–966) 728 (0–1375) p = 0.017
Total 566 (7–966) 798 (24–1427) p = 0.023
Numerical variables are shown as median (interquartile range); p < 0.05 is considered statistically significant
CA, celiac artery; CMI, chronic mesenteric ischemia; CTA, computed tomography angiography; IMA, inferior
mesenteric artery; kVp, kilovoltage peak;MACS, mesenteric artery calcium score;mm, millimeter; SMA, superior
mesenteric artery
Table 4 Test characteristics of
the mesenteric artery calcium
scores
MACS AUC (95% CI) Cutoff Sensitivity (%) Specificity (%) PPV (%) NPV (%)
CA 0.752 (0.674–0.830) 16.0 85.7 53.3 40.0 91.1
SMA 0.752 (0.668–0.835) 29.0 73.5 62.2 41.4 86.6
IMA 0.661 (0.570–0.753) 2.6 71.7 53.8 35.1 84.5
CA + SMA 0.767 (0.686–0.847) 29.7 87.8 51.9 39.8 92.1
Total 0.770 (0.690–0.851) 34.6 87.8 51.1 39.4 92.0
AUC, area under the curve; CA, celiac artery; CI, confidence interval; CMI, chronic mesenteric ischemia; IMA,
inferior mesenteric artery;MACS, mesenteric artery calcium score;NPV, negative predictive value; SMA, superior
mesenteric artery; PPV, positive predictive value
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This proof of principle study demonstrates the ability to
discriminate CMI patients from non-CMI patients using the
MACS (AUC 0.767). The MACS could be a promising
screening tool for CMI with a high sensitivity (87.8%) and
high NPV (92.0%), despite the mentioned limitations. These
results suggest that a low MACS rules out CMI and an in-
creased MACS warrants and justifies further diagnostic work-
up with a ≤ 1-mm CTA [8]. Correction for scan and recon-
struction parameters is needed, since we observed significant
differences in MACSs scored on two CTAs of the same pa-
tient acquired with a different scan and/or reconstruction pro-
tocol. Implementation and validation of an algorithm to cor-
rect for scan and reconstruction parameters seem to be the next
steps to further evaluate the clinical promise and applicability
of this tool.
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